Caenorhabditis elegans has been proven to be a useful model organism for investigating molecular and cellular aspects of numerous human diseases. More recently, investigators have explored the use of this organism as a tool for drug discovery. Although earlier drug screens were labor-intensive and low in throughput, recent advances in high-throughput liquid workflows, imaging platforms and data analysis software have made C. elegans a viable option for automated high-throughput drug screens. This review will outline the evolution of C. elegans-based drug screening, discuss the inherent challenges of using C. elegans, and highlight recent technological advances that have paved the way for future drug screens.

Original languageEnglish
Pages (from-to)247-253
Number of pages7
JournalAdvanced Drug Delivery Reviews
StatePublished - 2014


  • Clozapine (PubChem CID: 2818)
  • Drug target identification
  • Fluphenazine (PubChem CID: 3372)
  • High-throughput screening
  • Human disease models
  • Nemadipine-A (PubChem CID: 2856102)
  • Pharmaceuticals
  • Phenotypic analysis
  • Small molecules
  • Whole organism model


Dive into the research topics of 'C. elegans in high-throughput drug discovery'. Together they form a unique fingerprint.

Cite this